Posted by Michael Wonder on 14 Feb 2025
FDA approves vimseltinib for symptomatic tenosynovial giant cell tumour
14 February 2025 - Today, the FDA approved vimseltinib (Romvimza, Deciphera Pharmaceuticals), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumour for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
Efficacy was evaluated in MOTION, a double-blind, multi-centre, randomised (2:1), placebo-controlled trial in patients with tenosynovial giant cell tumour for whom surgical resection may cause worsening functional limitation or severe morbidity.
